DIVERSIFIED HEALTHCARE TRUST (DHC)
Real Estate · Healthcare REITs · NASDAQ
Diversified Healthcare Trust is a REIT focused on owning and operating a broad portfolio of senior living, medical office, and life science real estate properties across the U.S.
What DIVERSIFIED HEALTHCARE TRUST does
Diversified Healthcare Trust is a real estate investment trust (REIT) that owns a portfolio of healthcare-related properties throughout the United States. The company's assets consist primarily of senior living communities and life science, medical office, and biotech laboratory properties. It generates revenue through property rentals and the provision of resident fees and services at its managed healthcare facilities.
Themes: healthcare real estate, senior living, life sciences infrastructure, biotech real estate
Fundamentals
- Price$8.02 as of 2026-08-21 close
- Market cap$1.9B as of 2026-08-21
- 1-year return+125.3% 2025-08-21 close $3.56 → 2026-08-21 close $8.02
- P/En/a negative earnings
- Net margin-17.7% as of 2026-08-24
- Gross margin+19.7% as of 2026-08-24
- ROE-16.2% as of 2026-08-24
- Debt / equity1.52 as of 2026-08-24
- Revenue growth (YoY)-1.5% as of 2026-08-24
- Revenue CAGR (3y)+6.2% SEC XBRL
- Beta2.26 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.9%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How DHC compares in its sector
- net profit marginbottom 10% 161 covered Real Estate peers, as of 2026-08-24
- operating marginbottom 25% 161 covered Real Estate peers, as of 2026-08-24
- gross marginbottom 10% 156 covered Real Estate peers, as of 2026-08-24
- return on equitybottom 10% 162 covered Real Estate peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 155 covered Real Estate peers
- indicated dividend yieldbottom 10% 138 covered Real Estate peers, as of 2026-08-24
Position among covered Real Estate companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DHC is not currently in any published Top 10 list. Its scores are below.
Long-term score
47.3 #612 of 991 scored · #53 of 85 in Real Estate
Valuation 98th (price to book 0.7) and long-term trend 72nd (over the past 12 months this stock beat the market by 125.9 percentage points); weakest is profitability (2nd, operating margin -9.5%, return on equity -16.2%).
Short-term score
39.3 #1417 of 1,699 scored · #71 of 95 in Real Estate
Catalysts 59th: analysts have raised their average price target by 2.8% since the prior reading; volume and participation 44th: trading volume is about normal versus its 30-day average; weakest is setup 28th: no Elliott-wave labelling currently fits its swings.
Scores as of 18 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 1. DHC was not in the scored universe at the latest run on 21 Aug 2026, so these scores are its last ones.
Dividend coverage (FY2025)
Not assessable from available data. DHC paid a dividend in FY2025, but coverage cannot be assessed from the available data (non_positive_net_income, non_positive_operating_cash_flow).
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payoutnot assessable operating cash flow was not positive that year
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How DIVERSIFIED HEALTHCARE TRUST looks technically
DIVERSIFIED HEALTHCARE TRUST (DHC) is trading 15.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 290 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago. It is 17.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 15.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.89 | $8.89 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.94 | $6.94 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 9.66. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 290 trading days ago — a "golden cross", a bullish long-term signal | 290 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($7.89 to $9.33) — its "stochastic" reading is 9 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 9.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.66 | $9.66 |
|---|---|---|
| From the 52-week high | it is 17.0% below its 52-week high (its highest price of the past year) | -17.0% |
| Above the 52-week low | it is 138.0% above its 52-week low (its lowest price of the past year) | +138.0% |
| Below the 52-week high | it is 17.0% below its highest point of the past year | 17.0% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $29.99 (set on 2013-05-22) | $29.99 |
| Given back of the 52-week move | over the past year its closes ranged ($3.37 to $9.64), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.56 to $5.77. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.8% |
| From the all-time high | it is 73.3% below its all-time high | -73.3% |
| Nearest price level | it is trading 5.3% above a support level at $7.59 — a price it turned at three times since 2026-03-04, most recently on 2026-04-16. Since 2024-08-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.3% |
| All-time low | its lowest closing price on record is $0.61 (set on 2022-12-22) | $0.61 |
| Above the all-time low | it is 1214.8% above its all-time low | +1,215% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3553 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3553 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.75 and $9.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.75 – $8.59 – $9.44 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges above its 200-day average price (15.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.58× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Gap filled | a 4.5% gap down opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -0.99% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.1 percentage points (the stock lost 16.8% while the market gained 2.3%) | -19.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.0 percentage points (the stock lost 9.9% while the market gained 3.1%) | -13.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 17.5 percentage points (the stock gained 28.5% while the market gained 11.1%) | +17.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 104.8 percentage points (the stock gained 125.3% while the market gained 20.5%) | +104.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.8% of the share price. | -6.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.59 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +5.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.53 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | -6.0% |
Price levels it has turned at before
DHC last closed at $8.02 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.59 | Support | 5.3% below the last close | turned there three times · 2026-03-04 to 2026-04-16 |
| $6.88 | Support | 14.2% below the last close | turned there twice · 2026-02-18 to 2026-04-23 |
| $9.66 | Resistance | 20.4% above the last close | turned there twice · 2026-06-30 to 2026-07-22 |
| $4.63 | Support | 42.2% below the last close | turned there twice · 2025-12-11 to 2025-12-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $9.66.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · beating the market · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud · Completed Elliott five-wave sequences | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$10.15 range $8.00 – $11.50; median $10.55
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DHC
- Consensus EPS estimate-$0.13 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant debt obligations and potential challenges in refinancing or debt modification.","Historical net losses and ongoing dependency on operational performance in the senior living sector.","Exposure to fluctuations in property operating expenses and healthcare service costs."]
What changed in the latest 10-Q
AI-assisted comparison of DHC's 10-Q filed 2026-05-04 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-04) states portfolio consists of 285 properties in 33 states and Washington, D.C. as of March 31, 2026
- Newer filing (2026-05-04) adds statement that managers have 'opportunity to increase revenue in excess of increases in costs' (vs. older wording of 'increase rates')
- Newer filing (2026-05-04) presents Portfolio Overview table with NOI-based metrics showing SHOP at 57.5% of NOI, Medical Office at 33.0%, Triple net at 4.5%, Wellness at 5.0%
- Newer filing (2026-05-04) includes Comparable Properties table showing SHOP occupancy of 82.4% for comparable properties and 81.7% for all properties as of March 31, 2026
- Newer filing (2026-05-04) reports SHOP average monthly rate of $5,656 for comparable properties and $5,613 for all properties
- Newer filing (2026-05-04) shows Medical Office and Life Science Portfolio occupancy of 95.3% for comparable properties and 91.8% for all properties as of March 31, 2026
- Newer filing (2026-05-04) includes leasing activity table for three months ended March 31, 2026 showing 169 thousand square feet leased with 12.0% weighted average rental rate change
- Newer filing (2026-05-04) reports LSMD JV remaining lease term of 13.9 years (vs. 14.4 years in older filing)
- Removed:
- Older filing (2025-11-03) contained detailed disclosure about Five Star management transition announced September 3, 2025, with status updates as of September 30, 2025 and November 3, 2025—completely removed from newer filing
- Older filing (2025-11-03) listed 335 properties in 34 states as of September 30, 2025—replaced with 285 properties in 33 states in newer filing
- Older filing (2025-11-03) presented Portfolio Overview table organized by asset class with gross book value percentages and investment per unit/square foot metrics—replaced with different table structure in newer filing
- Older filing (2025-11-03) included occupancy data comparison between 2025 and 2024—not included in newer filing's comparable properties presentation
- Older filing (2025-11-03) presented separate leasing tables for three months and nine months ended September 30, 2025—newer filing presents only three-month period ended March 31, 2026
- Older filing (2025-11-03) included Lease Expiration Schedules section as of September 30, 2025—section appears truncated/incomplete in newer filing excerpt
- Reworded:
- Older filing (2025-11-03) lists properties as 'medical office and life science properties, senior living communities' in opening; newer filing (2026-05-04) reorders to 'senior living communities, medical office and life science properties'
- Older filing (2025-11-03) states managers should 'increase rates in excess of increases in costs'; newer filing (2026-05-04) states 'increase revenue in excess of increases in costs'
- Older filing (2025-11-03) presents portfolio overview table titled 'PORTFOLIO OVERVIEW' with asset-by-asset metrics; newer filing (2026-05-04) titled 'Portfolio Overview' with simplified segment-level metrics and adds separate 'Comparable Properties' table
- Notes:
- Newer filing is for three-month period ended March 31, 2026 (Q2 fiscal 2026); older filing is for nine-month period ended September 30, 2025 (Q3 fiscal 2025)—different reporting periods limit direct comparability
- Portfolio size and composition changed significantly between periods (335 to 285 properties), which may reflect dispositions, reclassifications, or held-for-sale status changes rather than operational changes
- Leasing data tables use different structures and time periods, making direct metric comparison difficult
- Older filing excerpt ends mid-sentence at 'Lease Expiration Schedules' section; newer filing excerpt also appears incomplete
Risk Factors
- Added:
- Newer filing (2026-05-04) includes a three-month period ended March 31, 2026 in the Condensed Consolidated Statements of Comprehensive Income, whereas older filing (2025-11-03) includes three-month and nine-month periods ended September 30, 2025 and 2024.
- Newer filing includes 'Purchase of interest rate cap ( 147 )' in cash flows from investing activities for the three months ended March 31, 2026.
- Newer filing shows 'Equity method investment distributions 27,200' in investing activities for three months ended March 31, 2026.
- Removed:
- Older filing includes extensive nine-month comparative data (nine months ended September 30, 2025 and 2024) in Comprehensive Income statement which is not present in newer filing.
- Older filing includes 'Payment of accreted interest on senior secured notes ( 86,992 )' in the nine-month cash flows, which does not appear in the three-month period in the newer filing.
- Older filing includes comparative balance sheet data as of September 30, 2025, which is replaced by March 31, 2026 data in newer filing.
- Older filing shows 'Assets of properties held for sale 258,389' and 'Liabilities of properties held for sale 17,604' which are shown as zero in newer filing.
- Older filing includes extensive shareholders' equity rollforward covering multiple quarters through September 30, 2025 and 2024; newer filing shows only the three-month period ending March 31, 2026.
- Reworded:
- Balance sheet date changed from 'September 30, 2025 and December 31, 2024' to 'March 31, 2026 and December 31, 2025'.
- Item reference page numbers changed from '54' to '39' for Risk Factors, Unregistered Sales, and Exhibits.
- Signature page changed from '56' to '41'.
- Comprehensive income statement header changed from covering three months and nine months ended September 30 to three months ended March 31.
- Shareholders' equity statement changed from detailed quarterly rollforward (December 31, 2024 through September 30, 2025) to simplified comparison (December 31, 2025 to March 31, 2026).
- Cash flows statement header changed from 'Nine Months Ended September 30' to 'Three Months Ended March 31'.
- Notes:
- These are different reporting periods with different financial data; the changes reflect the natural differences between a Q3 2025 filing and a Q1 2026 filing rather than changes in disclosure policy or accounting treatment.
- The comparison involves fundamentally different periods and comparative baselines, making period-to-period financial comparisons not directly meaningful without adjusting for the different fiscal periods covered.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-12-15. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DHC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
DHC had 13,705,792 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DHC had 5.66% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.54 days to cover at the same settlement.
- Reported short interest (shares) 13,705,792
- Short interest (% of shares outstanding) 5.66%
- Prior settlement (shares) 12,510,220
- Reported change 9.56%
- Days to cover (reported) 10.54
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Welltower (WELL)
- Ventas (VTR)
- Healthpeak Properties
- Omega Healthcare Investors (OHI)
- Sabra Health Care REIT (SBRA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DHC vs…
DIVERSIFIED HEALTHCARE TRUST is found in…
Frequently asked questions
What does DIVERSIFIED HEALTHCARE TRUST (DHC) do?
Diversified Healthcare Trust is a real estate investment trust (REIT) that owns a portfolio of healthcare-related properties throughout the United States. The company's assets consist primarily of senior living communities and life science, medical office, and biotech laboratory properties. It generates revenue through property rentals and the provision of resident fees and services at its managed healthcare facilities.
What sector is DIVERSIFIED HEALTHCARE TRUST (DHC) in?
DIVERSIFIED HEALTHCARE TRUST (DHC) is classified in the Real Estate sector. Its industry is Healthcare REITs. It trades on NASDAQ.
Does DHC pay a dividend?
Yes — DIVERSIFIED HEALTHCARE TRUST (DHC) pays a dividend, with an indicated yield of about 1.94% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are DIVERSIFIED HEALTHCARE TRUST's (DHC) competitors?
Notable peers of DIVERSIFIED HEALTHCARE TRUST (DHC) include Welltower, Ventas, Healthpeak Properties, Omega Healthcare Investors and Sabra Health Care REIT. This peer set is informational only — not financial advice.
Is DIVERSIFIED HEALTHCARE TRUST (DHC) overbought or oversold right now?
DIVERSIFIED HEALTHCARE TRUST (DHC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DHC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.